The DOI matches its Crossref record; 232 of the 232 references it cites were found in a registry or an index.
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Open accessAbstract
Parkinson disease (PD) treatment options have conventionally focused on dopamine replacement and provision of symptomatic relief. Current treatments cause undesirable adverse effects, and a large unmet clinical need remains for treatments that offer disease modification and that address symptoms resistant to levodopa. Advances in high-throughput drug screening methods for small molecules, developments in disease modelling and improvements in analytical technologies have collectively contributed to the emergence of novel compounds, repurposed drugs and new technologies. In this Review, we focus on disease-modifying and symptomatic therapies under development for PD. We review cellular therapies and repurposed drugs, such as nilotinib, inosine, isradipine, iron chelators and anti-inflammatories, and discuss how their success in preclinical models has paved the way for clinical trials. We provide an update on immunotherapies and vaccines. In addition, we review non-pharmacological interventions targeting motor symptoms, including gene therapy, adaptive deep brain stimulation (DBS) and optogenetically inspired DBS. Given the many clinical phenotypes of PD, individualization of therapy and precision of treatment are likely to become important in the future.Conventional therapies for Parkinson disease (PD) include dopamine replacement and therapies targeting symptomatic relief, but these approaches fail to modify the underlying disease. This Review explores the novel PD treatment strategies currently being investigated, including pharmaceuticals, cell therapies, immunotherapies, gene therapies and new technologies.Key pointsEmerging therapies for Parkinson disease (PD) have focused largely on disease modification and on dopamine resistance symptoms, which are both important unmet needs.Some new disease-modifying therapies target α-synuclein and its pathways, whereas others target different genes and proteins implicated in PD pathogenesis, including leucine-rich repeat kinase 2, parkin and glucocerebrosidase.Disease-modifying pharmacotherapies (such as nilotinib, inosine and isradipine) are being repurposed to treat PD; antibody therapies, vaccines and immune-mediated therapies that aim to clear abnormal proteins have also emerged as promising approaches.Cellular therapies can be divided into rescue and restoration therapies; rescue therapy aims to salvage neurons and slow the progression of the disease whereas restoration therapy focuses on replacing neurons.Adaptive deep brain stimulation is an alternative symptomatic therapy that can be used to target dopamine-responsive and dopamine-resistant symptoms.Current efforts to overcome challenges in therapeutic development have focused on individualization of therapy and precision in treatment; these principles are especially important given the heterogeneity of clinical PD subtypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T. T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019338 · Cited by 423
RetractedTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,205
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Cited by
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Oxidative Stress: Signaling Pathways, Biological Functions, and Disease
Liu, S., Liu, J., Wang, Y., Deng, F., & Deng, Z. (2025) · MedComm · doi:10.1002/mco2.70268 · Cited by 359
Development, wiring and function of dopamine neuron subtypes
Garritsen, O., van Battum, E. Y., Grossouw, L. M., & Pasterkamp, R. J. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00669-3 · Cited by 128
Lim, H.-S., Moon, B. C., Lee, J., Choi, G., & Park, G. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.07.010 · Cited by 30
S-MRUT: sectored-multiring ultrasonic transducer for selective powering of brain implants
Hosseini, S., Laursen, K., Rashidi, A., Mondal, T., Corbett, B., & Moradi, F. (2021) · IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control · doi:10.1109/tuffc.2020.3001084 · Cited by 15
Metadata
- Authors
- Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S.
- Venue
- Nature Reviews Neurology
- Published
- 2019-03-12
- Volume
- 15
- Issue
- 4
- Pages
- 204-223
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- OpenAlex
- W2921132745
- Cited by
- 300
- References
- 232
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging therapies in Parkinson disease — repurposed drugs and new approaches. https://app.cochat.ai/papers/10.1038/s41582-019-0155-7
- The paper
- Elkouzi, A., Vedam-Mai, V., Eisinger, R. S., & Okun, M. S. (2019). Emerging therapies in Parkinson disease — repurposed drugs and new approaches. Nature Reviews Neurology. https://doi.org/10.1038/s41582-019-0155-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.